Compare Incyte Corporation (INCY) vs CG Oncology, Inc. Common stock (CGON) Stock

Incyte Corporation (INCY) offers the better valuation at 15.8x trailing P/E (13.4x forward), making it the more compelling value choice. Analysts rate Incyte Corporation (INCY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, CG Oncology, Inc. Common stock (CGON) delivered a total return of +58.2%, compared to +27.2% for Incyte Corporation (INCY). A $10,000 investment in CGON five years ago would be worth approximately $16K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CGON returned +58.2% versus INCY's +37.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Incyte Corporation (INCY) is the lower-risk stock at 0.61β versus CG Oncology, Inc. Common stock's 1.55β — meaning CGON is approximately 154% more volatile than INCY relative to the S&P 500. On balance sheet safety, CG Oncology, Inc. Common stock (CGON) carries a lower debt/equity ratio of 0% versus 1% for Incyte Corporation — giving it more financial flexibility in a downturn.

Incyte Corporation (INCY) is the more profitable company, earning 25.0% net margin versus -77.3% for CG Oncology, Inc. Common stock — meaning it keeps 25.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INCY leads at 26.1% versus -100.7% for CGON. At the gross margin level — before operating expenses — CGON leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CGON: 34.4% to $79.00.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Incyte Corporation (INCY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.61)). CG Oncology, Inc. Common stock (CGON) carries a higher beta of 1.55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INCY: +37.8%, CGON: +58.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INCY is a mid-cap deep-value stock; CGON is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.